{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:21:18Z","timestamp":1787242878997,"version":"build-2736575974"},"reference-count":49,"publisher":"Informa UK Limited","issue":"10","funder":[{"name":"not funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2019,10,3]]},"DOI":"10.1080\/14712598.2019.1636963","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T14:52:56Z","timestamp":1561474376000},"page":"993-1000","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":32,"title":["Biosimilars for the treatment of psoriasis"],"prefix":"10.1080","volume":"19","clinical-trial-number":[{"clinical-trial-number":"nct02016105","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01970475","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02850965","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03210259","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01970488","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02660580","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02744755","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6083-0952","authenticated-orcid":false,"given":"Llu\u00eds","family":"Puig","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona,\r     Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"L\u00f3pez-Ferrer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona,\r     Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,7,1]]},"reference":[{"key":"CIT0001","unstructured":"Organization WH. Global report on       psoriasis. World Health Organization; s2016.\n      [accessed on 2019 May 4]. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/204417."},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.039"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17128"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-018-0230-9"},{"key":"CIT0006","unstructured":"Patent\n       expiry dates for biologicals: 2017\n     update - GaBI journal [WWW Document].\n      [accessed on 2019 May 4]. Available from: http:\/\/gabi-journal.net\/patent-expiry-dates-for-biologicals-2017-update.html"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15756"},{"key":"CIT0008","unstructured":"FDA approves 19th biosimilar, 2nd for\n      enbrel [WWW Document]. [accessed on 2019 May 4]. Available from: https:\/\/www.raps.org\/news-and-articles\/news-articles\/2019\/4\/fda-approves-19th-biosimilar-2nd-for-enbrel"},{"key":"CIT0009","unstructured":"biopharma-reporter.com. Biosimilars in the       US: rising applications and approval rates [WWW Document].\n      Biopharma-Reportercom. [accessed on 2019 May 4]. Available from: https:\/\/www.biopharma-reporter.com\/Article\/2019\/01\/11\/Biosimilar-applications-and-approvals-increase-in-the-US"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3427-2"},{"key":"CIT0011","unstructured":"Anonymous. Biosimilar medicines: overview       [WWW Document]. European Medicines Agency. 2018.\n      [accessed on 2019 May 4]. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/biosimilar-medicines-overview."},{"key":"CIT0012","unstructured":"Center\n       for Drug Evaluation and Research, FDA. Scientific       considerations in demonstrating biosimilarity to a reference product [WWW       Document]. 2019. [accessed on 2019        May 4]. Available from: URL\/regulatory-information\/search-fda-guidance-documents\/scientific-considerations-demonstrating-biosimilarity-reference-product."},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14267"},{"key":"CIT0014","first-page":"150","volume":"16","author":"Gerdes S","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"CIT0015","unstructured":"WHO |\n       Similar biotherapeutic products [WWW Document]. WHO.\n      [accessed on 2019 May 4]. Available from: http:\/\/www.who.int\/biologicals\/biotherapeutics\/similar_biotherapeutic_products\/en\/."},{"key":"CIT0016","unstructured":"Anonymous. Inflectra [WWW       Document]. European Medicines Agency. 2018.\n      [accessed on 2019 May 4]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/inflectra"},{"key":"CIT0017","unstructured":"Anonymous. Remsima [WWW       Document]. European Medicines Agency. 2018\n      [accessed on 2019 May 4]Availble from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/remsima"},{"key":"CIT0018","unstructured":"Research C for DE and biosimilar\n      product information.\n                      FDA\n                      2019. [accessed on 2019 May 4]. URL\/drugs\/biosimilars\/biosimilar-product-information"},{"key":"CIT0019","unstructured":"Anonymous. Flixabi [WWW       Document]. European Medicines Agency. 2018\n      [accessed on 2019 May 4]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/flixabi"},{"key":"CIT0020","unstructured":"Drug\n       Approval Package: Renflexis (infliximab-abda) [WWW Document].\n      [accessed on 2019 May 4]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761054Orig1s000TOC.cfm"},{"key":"CIT0021","unstructured":"Drug approval package: ixifi\n      (infliximab-qbtx) [WWW Document] .[accessed on 2019        May 4]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761072Orig1s000TOC.cfm"},{"key":"CIT0022","unstructured":"Anonymous. Benepali [WWW       Document]. European Medicines Agency. 2018\n      [accessed on 2019 May 4]. Availble from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/benepali"},{"key":"CIT0023","unstructured":"Anonymous. Erelzi [WWW       Document]. European Medicines Agency. 2018\n     Availble from [accessed on 2019 May 4]. Availble form: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/erelzi"},{"key":"CIT0024","unstructured":"Anonymous. Amgevita [WWW       Document]. European Medicines Agency. 2018\n      [accessed on 2019 May 4]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/amgevita"},{"key":"CIT0025","unstructured":"Anonymous. Solymbic [WWW       Document]. European Medicines Agency. 2018\n      [accessed on 2019 May 4]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/solymbic."},{"key":"CIT0026","unstructured":"Anonymous. Imraldi [WWW       Document]. European Medicines Agency. 2018\n      [accessed on 2019 May 4] Available from\n     https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/imraldi"},{"key":"CIT0027","unstructured":"Anonymous. Cyltezo [WWW       Document]. European Medicines Agency\n     2018. [accessed on 2019 May 4] Available from\n     https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cyltezo"},{"key":"CIT0028","unstructured":"Anonymous. Hyrimoz [WWW       Document]. European Medicines Agency. 2018.\n      [accessed on 2019 May 4] Available from\n     https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hyrimoz"},{"key":"CIT0029","unstructured":"Anonymous. Halimatoz [WWW       Document]. European Medicines Agency. 2018.\n      [accessed on 2019 May 4]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/halimatoz"},{"key":"CIT0030","unstructured":"Anonymous. Hefiya [WWW       Document].\n     European Medicines Agency. 2018. [accessed on       2019 May 4]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hefiya"},{"key":"CIT0031","unstructured":"Anonymous. Hulio [WWW       Document]. European Medicines Agency. 2018.\n      [accessed on 2019 May 4]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hulio"},{"key":"CIT0032","unstructured":"DIMITROVA EK. Idacio [WWW       Document]. European Medicines Agency. 2019.\n      [accessed on 2019 May 4]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/idacio"},{"key":"CIT0033","unstructured":"DIMITROVA EK. Kromeya [WWW       Document]. European Medicines Agency. 2019.\n      [accessed on 2019 May 4]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kromeya"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1288612"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2016.1217329"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15152"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14605"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.014"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15857"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16890"},{"key":"CIT0041","unstructured":"Efficacy, Safety and Immunogenicity of BI\n      695501 versus humira\u00ae in patients with moderate to severe chronic plaque psoriasis -\n      study results - ClinicalTrials.gov [WWW Document].\n      [accessed on 2019 May 4]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02850965"},{"key":"CIT0042","unstructured":"The VOLTAIRE-X trial looks at the effect\n      of switching between humira\u00ae and BI 695501 in patients with plaque . full text view\n      psoriasis- ClinicalTrials.gov [WWW Document].\n      [accessed on 2019 May 4]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03210259"},{"key":"CIT0043","unstructured":"MSB11022 in moderate to severe chronic\n      plaque psoriasis - study results - ClinicalTrials.gov [WWW       Document]. [accessed on 2019 May 4]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02660580"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15067"},{"key":"CIT0045","unstructured":"AbbVie signs another licensing deal for\n      adalimumab biosimilar\/pharma news\/home - GaBI onlineGenerics and\n      Biosimilars Initiative [WWW Document] [accessed on 2019        May 4]. Available from: http:\/\/www.gabionline.net\/Pharma-News\/AbbVie-signs-another-licensing-deal-for-adalimumab-biosimilar"},{"key":"CIT0046","unstructured":"Anonymous. Humira [WWW       Document]. European Medicines Agency. 2018.\n      [accessed on 2019 May 4]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/humira"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1002\/pst.1849"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-018-2418-4"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4090-6"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2019.1636963","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T19:52:55Z","timestamp":1599421975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2019.1636963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,1]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10,3]]}},"alternative-id":["10.1080\/14712598.2019.1636963"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2019.1636963","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-05-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}